SCHEMBL2029638

SCHEMBL2029638

CCNCc1ccc(OC)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.63
ALDH1A1 P00352 2/20 0.55
PKM P14618 1/20 0.55
GAA P10253 2/20 0.53
DPP7 Q9UHL4 2/20 0.51
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RAB9A P51151 2/20 0.50
IDO1 P14902 1/20 0.50
ATM Q13315 1/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121529 0.89 CHRM2 (0.70) CHRM2ALDH1A1PKMGAADPP7
Hydrochloric Acid SCHEMBL9479560 0.86 CHRM2 (0.68) CHRM2ALDH1A1PKMGAADPP7
Hydrochloric Acid SCHEMBL2147064 0.86 CHRM2 (0.68) CHRM2ALDH1A1PKMGAADPP7
SCHEMBL6050035 0.85 CHRM2 (0.49) CHRM2ALDH1A1PKMGAADPP7
SCHEMBL2938432 0.84 CHRM2 (0.78) CHRM2ALDH1A1PKMGAAKDM4E
1,4-Dimethoxybenzene SCHEMBL10989906 0.84 CA1 (0.61) CHRM2ALDH1A1GAAKDM4ERAB9A
SCHEMBL9180552 0.83 LMNA (0.52) CHRM2ALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL4030406 0.83 CHRM2 (0.70) CHRM2ALDH1A1PKMGAAKDM4E
SCHEMBL4919379 0.83 CHRM2 (0.81) CHRM2ALDH1A1PKMGAAKDM4E
SCHEMBL22305119 0.83 CHRM2 (0.63) CHRM2ALDH1A1PKMGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0806948-B1 TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN SEPRACOR INC (US) 2000-09-13 EP claimed
CN-1179714-A Treatment of urinary incontinence with (S) -oxybutynin and (S) -desethyloxybutynin SEPRACOR INC (US) 1998-04-22 CN claimed
EP-0806948-A1 TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN SEPRACOR, INC. (US) 1997-11-19 EP claimed
US-5677346-A Treating urinary incontinence using (S)-desethyloxybutynin SEPRACOR, INC. (US) 1997-10-14 US claimed
WO-1996023492-A1 TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN SEPRACOR, INC. (US) 1996-08-08 WO claimed
EP-0140886-A4 FILM BADGE FOR DETERMINING CARBONYL COMPOUNDS. LITTLE INC A (US) 1985-09-02 EP claimed
EP-0140886-A1 FILM BADGE FOR DETERMINING CARBONYL COMPOUNDS. LITTLE INC A (US) 1985-05-15 EP claimed
WO-1984004165-A1 FILM BADGE FOR DETERMINING CARBONYL COMPOUNDS LITTLE INC A (US) 1984-10-25 WO claimed
EP-4727944-A1 [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT Perha Pharmaceuticals (FR) 2026-04-22 EP disclosed
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 US disclosed
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2026-01-08 US disclosed
US-20250228854-A1 HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUNDS AND THEIR APPLICATIONS D3 BIO (WUXI) CO., LTD (CN) 2025-07-17 US disclosed
CN-119954725-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-05-09 CN disclosed
EP-4536350-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2025-04-16 EP disclosed
US-5028256-A Metolachlor and an acylamide compound, for maize or sorghum CIBA-GEIGY CORPORATION (US) 1991-07-02 US disclosed
US-4958029-A Process for the production of isoindoline derivatives, novel intermediates and process for their production BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-09-18 US disclosed
US-4897109-A ACYLAMINE DERIVATIVE CIBA-GEIGY CORPORATION (US) 1990-01-30 US disclosed
EP-0163607-B1 MEANS FOR THE PROTECTION OF CULTURE PLANTS AGAINST THE PHYTOTOXIC ACTION OF CHLORACETANILIDE HERBICIDES CIBA-GEIGY AG (CH) 1989-11-08 EP disclosed
EP-0275064-A2 Process for the production of isoindoline derivatives, novel intermediates and process for their production Banyu Pharmaceutical Co., Ltd. (JP) 1988-07-20 EP disclosed
EP-0163607-A2 Means for the protection of culture plants against the phytotoxic action of chloracetanilide herbicides CIBA-GEIGY AG (CH) 1985-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228854-A1 HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUNDS AND THEIR APPLICATIONS DPYD, TPMT, TYMP CHRM2 4711/4885ALDH1A1 147/4885PKM 823/4885
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NOD1, NLRP3, CASP1 CHRM2 3147/4885ALDH1A1 1139/4885PKM 4808/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 CHRM2 1455/4885ALDH1A1 618/4885PKM 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.